Todd A. Fehniger

Dr. Fehniger is a Professor of Medicine at Washington University School of Medicine who leads a basic, translational, and early phase clinical trial program focused on natural killer cell immunotherapy. He is the co-leader of the Siteman Cancer Center Lymphoma Program, Laboratory Director of the Center for Gene and Cellular Immunotherapy, and Director of the Biological Therapy Facility. As a physician-scientist, he has expertise in leukemia, lymphoma, cellular therapy, and hematopoietic cell transplantation. He has published more than 120 papers in these fields, has continuous NIH funding, and served as a Principal Investigator on a number of Phase 1 or 2 clinical trials of novel immunotherapy agents and cellular therapies over the past 14 years.

Dr. Fehniger’s research program focuses on understanding the fundamental biology of natural killer (NK) cell development and function, with the aim of developing and progressing novel immunotherapies and clinical trials to improve outcomes in patients with hematological and solid malignancies. This includes applying cutting-edge multidimensional approaches to advance the understanding of human immunology within patients. He is also interested in identifying somatic mutations that are associated with lymphoma pathogenesis and impact clinical outcomes, using this information to elucidate immune interactions and define neo-antigens, that may facilitate the development of novel immunotherapies augmenting the innate and adaptive immune responses. In addition to his research activities, Dr. Fehniger sits on the editorial boards of several journals, serves as the President of the Society for Natural Immunity, as well as holding several advisory positions at organizations developing NK cell-based immunotherapies.